

AN EVALUATION OF FIXED DOSE COMBINATIONS (FDCs) USED FOR TREATMENT DIABETES IN INDIAN MARKETSupreet Kamni^{1*}, Akram A Naikawadi², Anant Khot³

Received: Jan 2017

Revised: March 2017

Accepted: March 2017

¹Post graduate,²Professor and Head,³Associate Professor,Department of Pharmacology,
BLDEU's Shri B.M. Patil Medical
College and Research Centre,
Vijayapur, Karnataka, India.***Corresponding author:**

Dr. Anant Khot,

²Associate Professor,Department of Pharmacology,
BLDEU's Shri B.M. Patil Medical
College and Research Centre,
Vijayapur, Karnataka, India.Email: supreetkamni@gmail.com**ABSTRACT**

Objective: - To analyse the rationality of various FDCs used in the treatment Diabetes Mellitus and to find out the irrational FDCs existing in Indian market. **Material and Methods:** - Study Design: Analytical study. Data on FDC's available in the Indian market was collected from Current Index of Medical Specialities (CIMS) and Monthly Index of Medical Specialities (MIMS) and their rationality was analysed using a pretested tool based on FDCs listed in WHO essential list of medicines and National List of Essential Medicines (NLEM), others based on their pharmacodynamic activity, Pharmacokinetic parameters and significant drug interactions occurring due to API (Active pharmaceutical ingredients) contained within the product **Result:** A total of 18 combinations were analysed, among those 11 combinations were irrational. **Conclusion:** Predominantly irrational FDCs are being circulated in the Indian market hence through analyses by prescribers is needed before prescribing to patients in order to avoid ADR. This calls for a close scrutiny of marketed FDCs and educating prescribers to use them with great care and caution also indicates a serious review of regulatory framework for drug manufacturing and marketing.

KEYWORDS: Fixed Dose Combinations; Antidiabetics; Irrational.**INTRODUCTION**

Diabetes mellitus (DM), commonly referred to as diabetes is a group of metabolic diseases in which there are high blood sugar levels over a prolonged period. Globally, an estimated 422 million adults are living with diabetes mellitus, according to the latest 2016 data from the World Health Organization (WHO) [1].

Fixed dose combinations (FDCs) refer to products containing two or more active drugs used in a single dosage form for a particular indication [2]. Prescribing Fixed Dose Combinations (FDCs) in Diabetes mellitus treatment is a routine practice. Although FDCs are

associated with many advantages like synergistic action, reduced adverse effects, reduced pill burden, cost of the treatment and improved patients compliance [3] but certain disadvantages like incompatible pharmacokinetics, inflexible dose ratio and increased toxicity are limiting factors.

FDC is acceptable when the combination has proven advantage over single compound administered separately in terms of therapeutic efficacy or safety [4] Considering better patient compliance more and more physicians favour FDCs. As a result, pharmaceutical companies utilize this golden opportunity and market more and more combinations of which many of them are irrational.

MATERIALS & METHODS**Study Design:** observational and Analytical study**Sample:** Data on FDC's available in the Indian market was collected from Current Index of Medical Specialities (CIMS) and Monthly Index of Medical Specialities (MIMS).**Methods:** Rationality was analysed using a pretested tool based on FDCs listed in WHO essential list of medicines

ISSN: 2523-6695 (Print)

2523-6709 (Online)

This is an open access article distributed under the terms of the Creative Commons Attribution-Non-Commercial-Share Alike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: editor.ijcrpp@gmail.com

Cite this article as: Supreet Kamni, Akram A Naikwadi, Anant Khot. An evaluation of fixed dose combinations (FDCs) used for treatment diabetes in Indian market. *Int. J. Curr. Res. Physiol. Pharmacol.* 2018;2(1):6-9.

Tool to assess the rationality of fixed dose combinations

1. Active pharmacological ingredient along with strength

.....

.....

2. API

API

1	Approved by DCGI	Yes (+1)	No (-1)
2	Ingredient: Banned or Controversial	Yes (-1)	No (+1)

API = Active pharmacological ingredient, DCGI = Drug controller general of India

3. Listing in EML WHO/National/Both/None
(+1) (0)

4. Efficacy (text book/reference book/pub med/medline/ other)

1	API	Yes (+1)	No (0)
2	FDC	Yes (+1)	No (0)

API = Active pharmacological ingredient, FDC = Fixed dose combination

5. Safety (text book/reference book/pub med/medline/other)

1	API	Yes (+1)	No (0)
2	FDC	Yes (+1)	No (0)

API = Active pharmacological ingredient, FDC = Fixed dose combination

6. Pharmacokinetic (absorption/distribution/metabolism/ excretion/BA/BE/t ½)

- Interaction Favourable/Unfavourable/Not affected
(+1) (-1) (0)

7. Pharmacodynamic-M/A of each ingredient
Similar (0)/Different (+1)

8. Advantage of FDC

- Reduced Yes (+1) No (0)
- Less ADR Yes (+1) No (0)
- Convenient Yes (+1) No(0)
(frequency or pill count)

Total score: 12
Score ≥7: Rational FDC Score ≤6: Irrational FDC

& national list of essential medicines (NLEM) - on their pharmacodynamic activity, Pharmacokinetic parameters & significant drug interactions occurring due to API (Active pharmaceutical ingredients) contained within the product [5,6].

Analysis: All the quantitative variables have been expressed as mean and standard deviation and qualitative variables are expressed as percentages and proportions.

RESULTS

Total 18 FDCs were analysed. It was observed that 7 of the FDCs in antidiabetes drugs meet the criteria for rationality but there are 11 combinations found to be irrational.

Glibenclamide + metformin

Gliclazide + metformin

- Glimipride +metformin
- Glimipride + metformin + pioglitazone
- Glipizide + metformin
- Glibenclamide + metformin + pioglitazone
- Glibenclamide + metformin + volgibose
- Glimipride + metformin + Ramipril
- Glimipride + metformin + Ramipril + atrovastatin
- Glimipride + metformin + atrovastatin
- Metformin + fenofibrate




Fig 1. Shows the rational and irrational FDC




Fig 2. Shows percentages of different FDC's used irrationally

DISCUSSION

Sulfonylureas + Biguanides:

Pharmacokinetics: After oral administration, glimepiride is completely (100%) absorbed from the GI tract. Studies with single oral doses in normal subjects and with multiple

oral doses in patients with Type 2 diabetes have shown significant absorption of glimepiride within 1 hour after administration and peak drug levels (Cmax) at 2 to 3 hours. When glimepiride was given with meals, the mean Tmax (time to reach Cmax) was slightly increased (12%) and the mean Cmax and AUC (area under the curve) were slightly decreased (8% and 9%, respectively) [7].

Absorption of sulfonylureas is delayed by food and hyperglycemia

In view of time required to reach an optimal concentration in plasma, sulfonylureas are more effective when given 30min before food [8].

Antidiabetic + Antihypertensive + Hypolipidimics

A study conducted by Nisharan et. Al. showed that FDC when given in combination did not reach peak action of metformin, atrovastatin, and absorption of the metformin was reduced to only 80%, and delayed the absorption time which indicated the presence of interaction between these components [9].

They also violate some of the principles of formulation of FDCs like;

- a. Increased efficacy in comparison to the individual components given at the same dose,
- b. The incidence of adverse reactions in response to treatment with the combination is lower than in that in response to any of the component actives given alone,
- c. Improved adherence, simplified therapy,
- d. the actives in a combination should have similar pharmacokinetics. [10].

CONCLUSION

To conclude around 62% of the FDCs were found irrational. Indeed, it is very unfortunate and unethical to expose the innocent patients to medicines with unproven efficacy and safety. This calls for a close scrutiny of marketed FDCs and educating prescribers to use them with great care and caution. This also indicates a serious review of regulatory framework for drug manufacturing and marketing.

Financial Support and Sponsorship: Nil.

Conflicts of Interest: There are no conflicts of interest.

Acknowledgments: We are thankful to Department of Pharmacology, Shri B.M.Patil Medical College, Vijayapur for their guidance and help.

REFERENCES

1. World Health Organization, Global Report on Diabetes. Geneva, 2016. Accessed 30 August 2016[<http://www.who.int/diabetes/global-report/en/>]
2. Albert I, Wertheimer, Morrison A. Combination drugs: Innovation in Pharmacology. *Pharmacol and Ther*, 2002; 27(1): 46-49
3. Gautam CS, Aditya S. Irrational drug combination: need for student sensitization. *Ind J Pharmacol*. 2006; 38(3):169-70
4. Gautam C, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. *Br J Clin Pharmacol*. 2008; 65(5):795-796/795
5. Shah S, Patel J, Desai M, Dikshit R. Critical analysis of antimicrobial and respiratory fixed dose combinations available in Indian market. *International Journal of Medicine and Public Health*. 2015; 5(2):161-164.
6. Guidelines for registration of fixed-dose combination medicinal products. Geneva. World Health Organization 2005. Report number 929
7. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020496s021lbl.pdf
8. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Goodman and Gilman's the pharmacological basis of therapeutics, 12th edn, eds Brunton LL, Lazo JS, Parker KL New York: McGraw-Hill, 2011; 1255–1257.
9. Ranpise N, Jamkar P, Langote H. Formulation and Development of Fixed Dose Combination of Antihypertensive and Antidiabetic Agent for treatment of Co-existent Type Two Diabetes Mellitus and Hypertension. *Indian Journal of Pharmaceutical Education and Research*. 2014;48 (supplementary):114–22.
10. Guidelines on Fixed Dose Combinations (Fdc), Central Drugs Standard Control Organization India. April 2010 Page No 18 To 62 <http://cdsco.nic.in>